We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Protein Imbalance Linked to Presence of Biomarker in Tears of Sjögren’s Syndrome Patients

By LabMedica International staff writers
Posted on 17 May 2016
Increased expression of cathepsin S (CTSS) activity has emerged as a unique biomarker in the tears of Sjögren’s syndrome (SS) patients.

Sjögren’s syndrome, which affects mainly women, is an autoimmune disease caused by immune cells attacking the mucous membrane and fluid-secreting glands. More...
Although its characteristic symptoms are in the eyes and mouth, the disease is systemic and can damage other organs including kidney, liver, and brain. Patients with SS also have a higher risk of developing lymphoma.

Investigators at the University of Southern California (Los Angeles, USA) had previously identified increased CTSS activity as a unique characteristic of SS patient tears. Cathepsin S is a lysosomal enzyme that belongs to the papain family of cysteine proteases. While a role in antigen presentation has long been recognized, it is now understood that CTSS has a role in itch and pain, or nociception. The nociceptive activity results from CTSS functioning as a signaling molecule via activation of protease-activated receptors.

In the current study, the investigators evaluated the role of the proteins Rab3D, Rab27a, and Rab27b in the enhanced release of CTSS from cells in the tear glands (lacrimal gland acinar cells or LGAC).

In this study, the investigators worked with mice that had been genetically engineered to lack the gene for production of one or more of the Rab proteins. They reported in the April 13, 2016, online edition of the journal American Journal of Physiology—Cell Physiology that mice lacking the gene Rab3D had more cathepsin S in their tears while mice lacking Rab27 had less. The activities of Rab3D and Rab27 counteracted each other, and loss of Rab3D seemed to increase the influence of Rab27, contributing to the release of cathepsin S in the tears of patients with SS.

“We think that the large increase in tear cathepsin S is a fairly robust biomarker for Sjögren’s syndrome-mediated dry eye,” said senior author Dr. Sarah F.Hamm-Alvarez, professor of ophthalmology at the University of Southern California. “Earlier detection and treatment would offer the potential to prevent some of these serious systemic effects and the opportunity to prevent serious damage and loss of glandular tissue beyond repair.”

Related Links:
University of Southern California


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated PCR Setup
ESTREAM
New
Chlamydia Trachomatis Test
Aptima Chlamydia Trachomatis Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.